Literature DB >> 7996369

Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits.

M P Sherman1, L A Campbell, T A Merritt, W A Long, J H Gunkel, T Curstedt, B Robertson.   

Abstract

OBJECTIVES: To evaluate the effects of different surfactants on pulmonary infection with group B streptococci in premature rabbits and to examine the effects of different surfactants on pulmonary alveolar macrophage function of newborn rabbits. MODEL: Preterm and term rabbit pups.
METHODS: Rabbit pups were infected with GBS aerosols followed by intratracheal administration of either calf lung surfactant extract, minced porcine lung surfactant (Curosurf), synthetic surfactant (Exosurf Neonatal), minced bovine lung surfactant (Survanta), human amniotic fluid-derived surfactant, rabbit surfactant, saline vehicle, or no treatment. Intrapulmonary clearance of GBS was determined by comparing bacterial counts in left lungs cultured immediately after aerosol infection with similarly infected lungs analyzed 4 hours after surfactant therapy. Phagocytosis of streptococci was ascertained by microscopic examination of the right lungs fixed in situ at 4 hours. For comparison, an in vitro method was used to measure growth of GBS in the different surfactants.
RESULTS: Preterm animals had a sixfold increase in pulmonary bacterial growth compared with a slight decrease in intrapulmonary GBS in term animals when all were delivered by cesarean section (p < 0.05). In premature rabbits, GBS proliferation was lowest in animals treated with Exosurf Neonatal and highest in animals receiving Curosurf and human amniotic fluid-derived surfactant (p < 0.05). None of the surfactants promoted accelerated growth of GBS in comparison with control animals. Similar growth of GBS was seen in in vitro cultures. Intrapulmonary phagocytosis of GBS in premature pups was not altered by any of the surfactants. In term rabbit pups, the following measures of macrophage population kinetics remained normal at 1 and 24 hours after surfactant administration: viability, cell numbers based on lung lavage, and in vivo incorporation of thymidine.
CONCLUSIONS: Surfactants used in clinical practice do not accelerate the in vivo growth of group B streptococci in the lungs of preterm rabbits. Some surfactants inhibit streptococcal proliferation. The effects of different surfactants are not explained by changes in macrophage function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996369     DOI: 10.1016/s0022-3476(05)82013-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  Calfactant: a review of its use in neonatal respiratory distress syndrome.

Authors:  S V Onrust; M Dooley; K L Goa
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  New targets for surfactant replacement therapy: experimental and clinical aspects.

Authors:  B Robertson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

3.  Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants.

Authors:  B Jónsson; K Tullus; A Brauner; Y Lu; G Noack
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

Review 4.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

5.  Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia.

Authors:  E Herting; B Sun; C Jarstrand; T Curstedt; B Robertson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-01       Impact factor: 5.747

6.  Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period.

Authors:  P Rauprich; O Möller; G Walter; E Herting; B Robertson
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

Review 7.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 8.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

Review 9.  Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.

Authors:  Daniel Im; Wei Shi; Barbara Driscoll
Journal:  Front Pediatr       Date:  2016-03-30       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.